Epidemiology of Hematologic Malignancies in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study

Limited information is available on multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL) management in Latin America. The primary objective of the Hemato-Oncology Latin America (HOLA) study was to describe patient characteristics and treatment patterns of Latin A...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of global oncology Vol. 5; no. 5; pp. 1 - 19
Main Authors:	Tietsche de Moraes Hungria, Vania, Chiattone, Carlos, Pavlovsky, Miguel, Abenoza, Lina M, Agreda, Gladys P, Armenta, Jorge, Arrais, Celso, Avendaño Flores, Oscar, Barroso, Fernando, Basquiera, Ana L, Cao, Carmen, Cugliari, Maria S, Enrico, Alicia, Foggliatto, Laura M, Galvez, Kenny M, Gomez, David, Gomez, Alvaro, de Iracema, Daniel, Farias, Danielle, Lopez, Lineth, Mantilla, William Armando, Martínez, Deborah, Mela, Maria Jose, Miguel, Carlos E, Ovilla, Roberto, Palmer, Luis, Pavlovsky, Carolina, Ramos, Christian, Remaggi, Guillermina, Santucci, Rodrigo, Schusterschitz, Sergio, Sossa, Claudia Lucia, Tuna-Aguilar, Elena, Vela, Jorge, Santos, Telma, de la Mora, Odin, Machnicki, Gerardo, Fernandez, Mariana, Barreyro, Paula
Format:	Journal Article
Language:	English
Published:	United States American Society of Clinical Oncology 01-11-2019
Subjects:	Adult Aged Aged, 80 and over Humans Latin America - epidemiology Leukemia, Lymphocytic, Chronic, B-Cell - epidemiology Lymphoma, Non-Hodgkin - epidemiology Middle Aged Multiple Myeloma - epidemiology Original Reports Registries Young Adult Latin America
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Limited information is available on multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL) management in Latin America. The primary objective of the Hemato-Oncology Latin America (HOLA) study was to describe patient characteristics and treatment patterns of Latin American patients with MM, CLL, and NHL. This study was a multicenter, retrospective, medical chart review of patients with MM, CLL, and NHL in Latin America identified between January 1, 2006, and December 31, 2015. Included were adults with at least 1 year of follow-up (except in cases of death within 1 year of diagnosis) treated at 30 oncology hospitals (Argentina, 5; Brazil, 9; Chile, 1; Colombia, 5; Mexico, 6; Panama/Guatemala, 4). Of 5,140 patients, 2,967 (57.7%) had NHL, 1,518 (29.5%) MM, and 655 (12.7%) CLL. Median follow-up was 2.2 years for MM, 3.0 years for CLL, and 2.2 years for NHL, and approximately 26% died during the study observation period. Most patients had at least one comorbidity at diagnosis. The most frequent induction regimen was thalidomide-based chemotherapy for MM and chlorambucil with or without prednisone for CLL. Most patients with NHL had diffuse large B-cell lymphoma (DLBCL; 49.1%) or follicular lymphoma (FL; 19.5%). The majority of patients with DLBCL or FL received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. The HOLA study generated an unprecedented level of high-quality, real-world evidence on characteristics and treatment patterns of patients with hematologic malignancies. Regional disparities in patient characteristics may reflect differences in ethnoracial identity and level of access to care. These data provide needed real-world evidence to understand the disease landscape in Latin America and may be used to inform clinical and health policy decision making.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Undefined-2 V.T.d.M.H., C.C., and M.P. contributed equally to this study and its report.
ISSN:	2378-9506 2378-9506
DOI:	10.1200/JGO.19.00025